A comprehensive view of Genetic Disorders. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Premier Medical Laboratory Services adds noninvasive prenatal test that screens for chromosomal abnormalities such as Down Syndrome, indicates sex of baby, from blood sample; test is risk-free, highly accurate, covered by insurance for some pregnancies
Published: May 19, 2022 by PR Newswire
Pfizer starting Phase 3 study in US of injectable fordadistrogene movaparvovec mini-dystrophin gene therapy for ambulatory patients with Duchenne muscular dystrophy after FDA lifts clinical hold on drug; DMD has very limited treatment options
Published: May 09, 2022 by Contify Life Science News
Takeda’s injectable Takhzyro lanadelumab-flyo now available in US in single-dose prefilled syringes to prevent attacks of hereditary angioedema in adult, pediatric patients 12 years of age and older; HAE affects 1 in 50,000 people worldwide
Published: April 25, 2022 by ENP Newswire
FDA approves Novartis’ 170,000 square-foot, multi-product gene therapy manufacturing plant in Durham, North Carolina; plant to make injectable Zolgensma onasemnogene abeparvovec to treat spinal muscular atrophy, a leading genetic cause of infant death
Published: April 12, 2022 by Novartis AG
Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling
Published: March 28, 2022 by Takeda Pharmaceutical Co. Ltd.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count